成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart Sign in  
Chemical Structure| 503176-50-9 Chemical Structure| 503176-50-9

Structure of 503176-50-9

Chemical Structure| 503176-50-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 503176-50-9

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 503176-50-9 ]

CAS No. :503176-50-9
Formula : C13H16BFO3
M.W : 250.07
SMILES Code : O=CC1=CC=C(B2OC(C)(C)C(C)(C)O2)C=C1F
MDL No. :MFCD16036135
InChI Key :IIFHCQXSBTZOCF-UHFFFAOYSA-N
Pubchem ID :53217113

Safety of [ 503176-50-9 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 503176-50-9 ] Show Less

Physicochemical Properties

Num. heavy atoms 18
Num. arom. heavy atoms 6
Fraction Csp3 0.46
Num. rotatable bonds 2
Num. H-bond acceptors 4.0
Num. H-bond donors 0.0
Molar Refractivity 68.26
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

35.53 ?2

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

0.0
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

2.47
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

2.36
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.45
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

2.44
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.74

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-3.06
Solubility 0.217 mg/ml ; 0.000869 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.86
Solubility 0.345 mg/ml ; 0.00138 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-4.23
Solubility 0.0147 mg/ml ; 0.0000589 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

 High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

 Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

 Yes
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

 No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

 No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

 No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

 No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

 No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.07 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

 0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

 None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

 0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

 0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

 0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

2.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

 No; 1 violation:MW<0.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

 2.78

Application In Synthesis of [ 503176-50-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 503176-50-9 ]

[ 503176-50-9 ] Synthesis Path-Downstream   1~12

  • 1
  • 3-fluoro-4-formylphenylboronic acid [ No CAS ]
  • [ 76-09-5 ]
  • [ 503176-50-9 ]
  • 2
  • [ 503176-50-9 ]
  • [ 95-55-6 ]
  • [ 1194384-92-3 ]
  • 3
  • [ 503176-50-9 ]
  • [ 1403674-45-2 ]
  • C39H45FN2O3S [ No CAS ]
  • 4
  • [ 503176-50-9 ]
  • (S)-4-(5-bromopyrimidin-2-yl)-2-((6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl)morpholine [ No CAS ]
  • (S)-4-(5-(3-fluoro-4-((4-methylpiperazin-1-yl)methyl)phenyl)pyrimidin-2-yl)-2-((6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl)morpholine [ No CAS ]
  • 5
  • [ 57848-46-1 ]
  • [ 73183-34-3 ]
  • [ 503176-50-9 ]
YieldReaction ConditionsOperation in experiment
96% With 1,1'-bis-(diphenylphosphino)ferrocene; (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium acetate; In 1,4-dioxane; at 85℃; for 13.0h;Inert atmosphere; 2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)benzaldehyde In a pressure tube reactor, 4-bromo-2-fluorobenzaldehyde (500 mg, 2.46 mmol) and 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (938 mg, 3.69 mmol) were added, and then Pd(dppf)2Cl2 (120 mg, 0.15 mmol) was added. dppf (78 mg, 0.15 mmol) and KOAC (965 mg, 9.84 mmol) were further added, and 1,4-dioxane (8 mL) was added, followed by stirring at 85 C. under nitrogen gas for 13 hours. When the reaction was completed, the reaction mixture was extracted two times or more with ethyl acetate and water, and the organic layer was treated with sodium sulfate to remove extra water. After concentration under reduced pressure, column chromatography using 20% ethyl acetate/hexane gave 2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)benzaldehyde with a yield of 96%. 1H-NMR (300 MHz, CDCl3) delta 10.38 (s, 1H), 7.85-7.81 (m, 1H), 7.67-7.65 (m, 1H), 7.57 (s, J=10.4 Hz, 1H), 1.35 (s, 12H)
96% With 1,1'-bis-(diphenylphosphino)ferrocene; palladium bis[bis(diphenylphosphino)ferrocene] dichloride; potassium acetate; In 1,4-dioxane; water; at 85℃; for 13.0h;Inert atmosphere; [0285] In a pressure tube reactor 4-Bromo-2-fluorobenzaldehyde (500 mg, 2.46 mmol) and 4,4,4 ', 4', 5,5,5 ', 5'-octamethyl-2,2'-bi (1,3,2-dioxaborolane) (938 mg, 3.69 mmol) was added thereto, Pd (dppf) 2Cl2 (120 mg, 0.15 mmol) was added, Dppf (78 mg, 0.15 mmol) and KOAC (965 mg, 9.84 mmol) were further added, 1.4-dioxane (8 mL) was added, 85 In the mixture was stirred for 13 hours. After the reaction was completed, the reaction mixture was extracted twice with ethyl acetate and water, and then the organic layer was washed with anhydrous magnesium sulfate to remove excess water. Concentrated under reduced pressure and subjected to column chromatography with 20% ethyl acetate / nucleic acid to obtain 2-fluoro-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzaldehyde Was obtained in 96% yield.
  • 6
  • [ 503176-50-9 ]
  • (S)-5-(1-((4-(5-bromopyrimidin-2-yl)morpholine-2-yl)methyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-2-fluorobenzonitrile [ No CAS ]
  • (S)-2-fluoro-5-(1-((4-(5-(3-fluoro-4-formylphenyl)pyrimidin-2-yl)morpholin-2-yl)methyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)benzonitrile [ No CAS ]
YieldReaction ConditionsOperation in experiment
90% With tetrakis(triphenylphosphine) palladium(0); sodium carbonate; In 1,4-dioxane; at 20 - 105℃; for 3.16667h;Inert atmosphere; (S)-2-fluoro-5-(1-((4-(5-(3-fluoro-4-formylphenyl)pyrimidin-2-yl)morpholin-2-yl)methyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)benzonitrile In a pressure tube reactor, ((S)-5-(1-((4-(5-bromopyrimidin-2-yl)morpholine-2-yl)methyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-2-fluorobenzonitrile (50 mg, 0.10 mmol) was added, and then 1M Na2CO3 (0.31 mL, 0.31 mmol) was added. Pd(PPh3)4 (6 mg, 0.005 mmol) was further added, and 1,4-dioxane (1 mL) and <strong>[503176-50-9]2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)benzaldehyde</strong> (38 mg, 0.15 mmol) were added. The mixture was stirred at room temperature for 10 minutes under nitrogen gas, and then stirred at 105 C. for 3 hours. When the reaction was completed, the organic layer was extracted with ethyl acetate and water, and the extra water was removed by sodium sulfate, followed by concentration under reduced pressure. Solid was generated using ether and hexane, followed by filtration, to give (S)-2-fluoro-5-(1-((4-(5-(3-fluoro-4-formylphenyl)pyrimidin-2-yl)morpholin-2-yl)methyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)benzonitrile (49 mg, 0.091 mmol) with a yield of 90%. 1H-NMR (300 MHz, CDCl3) delta 10.36 (s, 1H), 9.19 (s, 1H), 8.53-8.45 (m, 1H), 8.61 (s, 2H), 7.97-7.92 (m, 1H), 7.49-7.39 (m, 3H), 5.08-5.01 (m, 1H), 4.94-4.88 (m, 1H), 4.56 (d, J=12.9 Hz, 1H), 4.27 (brs, 1H), 4.01-3.93 (m, 1H), 3.67-3.56 (m, 1H), 3.27-3.09 (m, 2H)
90% With tetrakis(triphenylphosphine) palladium(0); sodium carbonate; In 1,4-dioxane; at 20 - 105℃; for 3.0h;Inert atmosphere; [0288] In a pressure tube reactor ((S) -5- (1 - ((4- (5- bromopyrimidin-2-yl) morpholin-2-yl) methyl) -1H- [1,2,3] triazolo [4, 5-b] pyrazin-6-yl) -2-fluorobenzonitrile 50 mg, 0.10 mmol), followed by the addition of 1M Na2CO3 (0.31 mL, 0.31 mmol). Pd (PPh3) 4 (6 mg, 0.005 mmol) was further added thereto, and 1,4-dioxane (1 mL) and 2-fluoro-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzaldehyde (38 mg, 0.15 mmol), and the mixture was stirred at room temperature under nitrogen gas for 10 minutes, Followed by stirring at 105 DEG C for 3 hours. When the reaction was completed, the organic layer was extracted with ethyl acetate and water, and the excess water was removed with anhydrous magnesium sulfate, followed by concentration under reduced pressure. The solid was formed using ether and hexane and then filtered (S) -2-fluoro-5- (l- (4- (5- (3-fluoro-4-formylphenyl) pyrimidin- [L, 2,3] triazolo [4,5-b] pyrazin-6-yl) benzonitrile (49 mg, 0.091 mmol) was obtained in 90% yield
  • 7
  • [ 503176-50-9 ]
  • (S)-2-fluoro-5-(1-((4-(5-(3-fluoro-4-((4-methylpiperazin-1-yl)methyl)phenyl)pyrimidin-2-yl)morpholine-2-yl)methyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)benzonitrile [ No CAS ]
  • 8
  • [ 503176-50-9 ]
  • (S)-4-(5-bromopyrimidin-2-yl)-2-((6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl)morpholine [ No CAS ]
  • 2-fluoro-4-{2-[(2S)-2-[6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl]methyl}morpholin-4-yl]pyrimidin-5-yl}benzaldehyde [ No CAS ]
YieldReaction ConditionsOperation in experiment
76% With tetrakis(triphenylphosphine) palladium(0); sodium carbonate; In 1,4-dioxane; at 20 - 105℃; for 13.1667h;Inert atmosphere; (S)-2-fluoro-4-(2-(2-((6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl)morpholino)pyrimidin-5-yl)benzaldehyde In a pressure tube reactor, (S)-4-(5-bromopyrimidin-2-yl)-2-((6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl)morpholine (50 mg, 0.11 mmol) was added, and then 1M Na2CO3 (0.33 mL, 0.33 mmol) was added. Pd(PPh3)4 (6 mg, 0.005 mmol) was further added, and then 1,4-dioxane (1 mL) and <strong>[503176-50-9]2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)benzaldehyde</strong> (41 mg, 0.16 mmol) were added. The mixture was stirred at room temperature for 10 minutes under nitrogen gas, and then stirred at 105 C. for 13 hours. When the reaction was completed, the organic layer was extracted with ethyl acetate and water, and the extra water was removed by sodium sulfate, followed by concentration under reduced pressure. Solid was generated using ether and hexane, followed by filtration, to give (S)-2-fluoro-4-(2-(2-((6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)-methyl)morpholino)pyrimidin-5-yl)benzaldehyde (41 mg, 0.087 mmol) with a yield of 76%. 1H-NMR (300 MHz, CDCl3) delta 10.36 (s, 1H), 8.92 (s, 1H), 8.59 (s, 2H), 8.17 (s, 1H), 8.12 (s, 1H), 7.94 (t, J=7.56 Hz, 1H), 7.36 (d, J=8.1 Hz, 1H), 4.99-4.92 (m, 1H), 4.85-4.79 (m, 1H), 4.54 (d, J=12.9 Hz, 1H), 4.27 (brs, 1H), 4.02 (s, 3H), 3.64-3.56 (m, 1H), 3.28-3.13 (m, 2H)
76% With tetrakis(triphenylphosphine) palladium(0); sodium carbonate; In 1,4-dioxane; at 20 - 105℃; for 13.1h;Inert atmosphere; [0295] In a pressure tube reactor (S) -4- (5- bromopyrimidin-2-yl) -2 - ((6- (1-methyl -1H- pyrazol-4-yl) -1H- [1,2,3] triazole pyrazolo [4,5- b] pyrazin-1-yl) methyl) morpholine (50 mg, 0.11 mmol) was added, followed by the addition of 1 M Na2CO3 (0.33 mL, 0.33 mmol) . Pd (PPh3) 4 (6 mg, 0.005 mmol) was further added, and 1,4-dioxane (1 mL) and 2-fluoro-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzaldehyde (41 mg, 0.16 mmol), and the mixture was stirred at room temperature under nitrogen gas for 10 minutes and then at 105 DEG C for 13 hours. After the reaction was completed, the organic layer was extracted with ethyl acetate and water, and the excess water was removed with anhydrous magnesium sulfate and concentrated under reduced pressure. (S) -2-fluoro-4- (2- (2 - ((6- (1 -methyl-1 H-pyrazol-4-yl) -1H Yl) benzaldehyde (41 mg, 0.087 mmol) was obtained in 76% yield according to a procedure similar to that used for the synthesis of .
  • 9
  • [ 503176-50-9 ]
  • 4-(5-bromothiophen-2-yl)-2-fluorobenzaldehyde [ No CAS ]
  • 10
  • [ 503176-50-9 ]
  • C41H42FNO2S2 [ No CAS ]
  • 11
  • [ 503176-50-9 ]
  • (E)-2-cyano-3-(2-fluoro-4-(5-(10-hexyl-7-(4-(hexyloxy)phenyl)-10H-phenothiazin-3-yl)thiophen-2-yl)phenyl)acrylic acid [ No CAS ]
  • 12
  • [ 1003-09-4 ]
  • [ 503176-50-9 ]
  • 2-fluoro-4-(thiophen-2-yl)benzaldehyde [ No CAS ]
YieldReaction ConditionsOperation in experiment
63% With potassium phosphate; tetrakis(triphenylphosphine) palladium(0); In tetrahydrofuran; water; toluene; at 80℃; for 3.0h;Inert atmosphere; A three-necked flask was charged with 2-bromothiophene (2.7 g, 16.7 mmol)2-fluoro-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzaldehyde (5.0 g, 20.0 mmol)Pd (PPh3) 4 (0.7 g, 0.6 mmol), K3PO4H2O (12.7 g, 60.0 mmol),Toluene (50 mL), tetrahydrofuran (THF, 35 mL),Distilled water (25 mL) is added and reacted at 80 C for 3 hours under nitrogen.After the reaction is completed, ethyl acetate (EA) is added at room temperature to remove the product, which is then extracted with MgSO 4, and the solvent is distilled off. The solution thus obtained was purified by column chromatography using silica gel to obtain a yellow solid substance 7-1 (2.16 g, 63% yield).
 

Related Products

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 503176-50-9 ]

Fluorinated Building Blocks

Chemical Structure| 1844839-22-0

A257082 [1844839-22-0]

4-Fluoro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde

Similarity: 0.88

Chemical Structure| 1008119-07-0

A124916 [1008119-07-0]

2,6-Difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid

Similarity: 0.87

Chemical Structure| 1082066-29-2

A176243 [1082066-29-2]

(2-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanol

Similarity: 0.85

Chemical Structure| 1192548-08-5

A105748 [1192548-08-5]

2-(2-Fluoro-3-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

Similarity: 0.81

Chemical Structure| 870238-67-8

A214282 [870238-67-8]

2-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile

Similarity: 0.81

Organoborons

Chemical Structure| 1844839-22-0

A257082 [1844839-22-0]

4-Fluoro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde

Similarity: 0.88

Chemical Structure| 1008119-07-0

A124916 [1008119-07-0]

2,6-Difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid

Similarity: 0.87

Chemical Structure| 1082066-29-2

A176243 [1082066-29-2]

(2-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanol

Similarity: 0.85

Chemical Structure| 1192548-08-5

A105748 [1192548-08-5]

2-(2-Fluoro-3-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

Similarity: 0.81

Chemical Structure| 870238-67-8

A214282 [870238-67-8]

2-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile

Similarity: 0.81

Aryls

Chemical Structure| 1844839-22-0

A257082 [1844839-22-0]

4-Fluoro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde

Similarity: 0.88

Chemical Structure| 1008119-07-0

A124916 [1008119-07-0]

2,6-Difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid

Similarity: 0.87

Chemical Structure| 1082066-29-2

A176243 [1082066-29-2]

(2-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanol

Similarity: 0.85

Chemical Structure| 1192548-08-5

A105748 [1192548-08-5]

2-(2-Fluoro-3-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

Similarity: 0.81

Chemical Structure| 870238-67-8

A214282 [870238-67-8]

2-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile

Similarity: 0.81

Aldehydes

Chemical Structure| 1844839-22-0

A257082 [1844839-22-0]

4-Fluoro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde

Similarity: 0.88

Chemical Structure| 380151-86-0

A173594 [380151-86-0]

3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde

Similarity: 0.81

Chemical Structure| 128376-64-7

A188411 [128376-64-7]

4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde

Similarity: 0.81

Chemical Structure| 380151-85-9

A117333 [380151-85-9]

2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde

Similarity: 0.80

Chemical Structure| 1416721-24-8

A111294 [1416721-24-8]

2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-4-(trifluoromethyl)benzaldehyde

Similarity: 0.78